Sunrise Medical is a world leader in the development, design, manufacture and distribution of manual wheelchairs, power wheelchairs, motorized scooters and both standard and customized seating and positioning systems. Sunrise Medical manufactures products in its own facilities in the United States, Mexico, Germany, United Kingdom, Spain , Holland, Poland, and China. Sunrise Medical's key products, marketed under the Quickie, Sopur, Zippie, Breezy, Sterling , JAY and Coopers proprietary brands, are sold through a network of homecare medical product dealers or distributors in over 130 countries. Sunrise Medical is headquartered in Malsch, Germany with North American headquarters in Fresno, California and employs over 2,000 asociates worldwide.
Neuronetics, Inc., is the creator of NeuroStar Advanced Therapy, the market leader in Transcranial Magnetic Stimulation (TMS) for the treatment of Major Depressive Disorder. Based in Malvern, PA, we are a public medical device company (STIM) with a strategic vision of transforming the lives of patients whenever and wherever they need it with the best neurohealth therapies in the world.
NeuroStar is the #1 TMS choice of doctors, with over 4.3 million treatments performed to date. It is an advanced treatment for depression. It is not medication, shock therapy, or surgery. NeuroStar is an outpatient treatment done in as little as 20 minutes for 36 sessions. It promotes neuroplasticity to target depression where it starts — the brain.
Neuronetics markets NeuroStar Advanced Therapy throughout the United States and select markets around the world.
If you have questions or comments about NeuroStar, please e-mail us at customersupport@neurostar.com. For U.S. phone support, please call us at (877) 600-7555, for international customers, our number is +1 (610) 640-4207.
Please visit NeuroStar.com/Safety for full safety and prescribing information.
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives.
BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction.
The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS.
For the latest news and information about BrainsWay, please visit www.brainsway.com.